作者
Jehan Dupuis, Franck Morschhauser, Hervé Ghesquières, Hervé Tilly, Olivier Casasnovas, Catherine Thieblemont, Vincent Ribrag, Céline Bossard, Fabien Le Bras, Emmanuel Bachy, Bénédicte Hivert, Emmanuelle Nicolas-Virelizier, Fabrice Jardin, Jean-Noel Bastie, Sandy Amorim, Julien Lazarovici, Antoine Martin, Bertrand Coiffier
发表日期
2015/4/1
期刊
The Lancet Haematology
卷号
2
期号
4
页码范围
e160-e165
出版商
Elsevier
简介
Background
Romidepsin is a histone deacetylase inhibitor approved in the USA for patients with recurrent or refractory peripheral T-cell lymphoma and has shown activity in this setting with mainly haematological and gastrointestinal toxicity. Although it has limited efficacy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used for treatment of de-novo peripheral T-cell lymphoma. We aimed to assess the safety, tolerability, and activity of romidepsin combined with CHOP in patients with previously untreated disease.
Methods
We enrolled patients aged 18–80 years with histologically proven, previously untreated, peripheral T-cell lymphoma (Eastern Cooperative Oncology Group performance status ≤2) into a dose-escalation (phase 1b) and expansion (phase 2) study at nine Lymphoma Study Association centres in France. In the dose-escalation phase, we allocated consecutive …
学术搜索中的文章
J Dupuis, F Morschhauser, H Ghesquières, H Tilly… - The Lancet Haematology, 2015